NASDAQ:MNKD - MannKind Stock Price, Price Target & More

$1.70 -0.09 (-5.03 %)

(As of 04/22/2018 06:48 AM ET)

Previous Close$1.70

Today's Range$1.67 - $1.7999

52-Week Range$0.67 - $6.96

Volume3.67 million shs

Average Volume2.60 million shs

Market Capitalization$226.19 million

P/E RatioN/A

Dividend YieldN/A

Beta2.91

About MannKind (NASDAQ:MNKD)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:MNKD

CUSIP56400P20

Webwww.mannkindcorp.com

Phone818-661-5000

Debt

Debt-to-Equity Ratio-0.48%

Current Ratio0.65%

Quick Ratio0.62%

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.74 million

Price / Sales19.27

Cash FlowN/A

Price / CashN/A

Book Value($1.81) per share

Price / Book-0.94

Profitability

EPS (Most Recent Fiscal Year)($1.16)

Net Income$-117,330,000.00

Net Margins-999.00%

Return on EquityN/A

Return on Assets-159.22%

Miscellaneous

Employees250

Outstanding Shares133,050,000

How to Become a New Pot Stock Millionaire

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) posted its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $4.53 million for the quarter, compared to analysts' expectations of $3.22 million. View MannKind's Earnings History.

When is MannKind's next earnings date?

MannKind is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for MannKind.

What price target have analysts set for MNKD?

4 brokerages have issued twelve-month target prices for MannKind's stock. Their forecasts range from $1.00 to $2.77. On average, they anticipate MannKind's stock price to reach $1.59 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:

1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (4/6/2018)
2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest in March. As of March 29th, there was short interest totalling 35,944,357 shares, an increase of 1.2% from the March 15th total of 35,523,152 shares. Based on an average daily volume of 1,481,058 shares, the days-to-cover ratio is currently 24.3 days. Currently, 34.6% of the company's shares are short sold.

Who are some of MannKind's key competitors?

Some companies that are related to MannKind include Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Dermira (DERM), Clearside Biomedical (CLSD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK) and Merus (MRUS).

Who are MannKind's key executives?

MannKind's management team includes the folowing people:

Dr. Michael E. Castagna, CEO & Director (Age 41)
Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
Mr. Steven B. Binder, Chief Financial Officer (Age 55)
Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)

Has MannKind been receiving favorable news coverage?

Media stories about MNKD stock have been trending positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MannKind earned a news impact score of 0.44 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are MannKind's major shareholders?

MannKind's stock is owned by a number of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $1.70.

How big of a company is MannKind?

MannKind has a market capitalization of $226.19 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]

MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:		2.1 out of 5 ( )
Outperform Votes:		335 (Vote Outperform)
Underperform Votes:		446 (Vote Underperform)
Total Votes:		781

MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.

MannKind (NASDAQ:MNKD) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $1.59, suggesting that the stock has a possible downside of 6.47%. The high price target for MNKD is $2.77 and the low price target for MNKD is $1.00. There are currently 3 sell ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.50	1.50	1.75	2.00
Ratings Breakdown:	3 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	2 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$1.59	$1.59	$0.9150	$0.9150
Price Target Upside:	6.47% downside	49.68% downside	71.85% downside	75.27% downside

MannKind (NASDAQ:MNKD) Consensus Price Target History

Price Target History for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/28/2018	Maxim Group	Downgrade	Hold -> Sell	$1.00	High
1/25/2018	S&P Equity Research	Lower Price Target		$3.49 -> $2.77	High
11/8/2017	HC Wainwright	Reiterated Rating	Buy		N/A
5/22/2017	JPMorgan Chase	Reiterated Rating	Underweight		High
5/11/2017	Piper Jaffray	Set Price Target	Sell	$1.00	Medium
6/1/2016	Royal Bank of Canada	Lower Price Target	Underperform	$1.00 -> $0.15	N/A
4/28/2016	JMP Securities	Reiterated Rating	Hold		N/A

(Data available from 4/22/2016 forward)

MannKind (NASDAQ:MNKD) Earnings History and Estimates Chart

Earnings by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ:MNKD) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.85 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

MannKind (NASDAQ MNKD) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/9/2018
2/27/2018	Q4 2017	($0.29)	($0.28)	$3.22 million	$4.53 million	View	N/A
11/7/2017	Q3 2017	($0.20)	($0.31)	$2.56 million	$2.04 million	View	N/A
8/7/2017	Q2 2017	($0.25)	($0.35)	$2.75 million	$2.16 million	View	Listen
5/10/2017	Q1 2017	($0.09)	($0.17)	$3.50 million	$3.00 million	View	N/A
3/16/2017	Q4 2016	($0.20)	($0.19)	$6.00 million	$12.40 million	View	N/A
11/9/2016	Q3 2016	($0.06)	$0.26	$2.00 million	$162.35 million	View	Listen
8/8/2016	Q2	($0.06)	($0.07)	$0.03 million		View	N/A
5/9/2016	Q116	($0.04)	($0.06)			View	N/A
3/14/2016	Q4	($0.05)	($0.66)	$0.35 million		View	N/A
11/9/2015	Q315	($0.07)	($0.08)			View	N/A
8/10/2015	Q215	($0.08)	($0.07)	$0.53 million		View	Listen
5/7/2015	Q115	($0.08)	($0.08)	$5.40 million		View	Listen
2/24/2015	Q414	($0.09)	($0.09)	$3.13 million		View	Listen
11/3/2014	Q314	$0.09	($0.09)	$66.60 million		View	Listen
8/11/2014	Q214	($0.11)	($0.19)			View	Listen
5/12/2014	Q114	($0.13)	($0.14)			View	Listen
2/18/2014	Q4	($0.14)	($0.16)	$0.43 million		View	Listen
11/4/2013	Q313	($0.14)	($0.17)			View	Listen
8/9/2013	Q2 2013	($0.14)	($0.16)			View	N/A
5/9/2013	Q1 2013	($0.15)	($0.15)			View	Listen
2/11/2013	Q4 2012	($0.19)	($0.23)			View	Listen
11/1/2012	Q312	($0.24)	($0.22)			View	N/A
8/7/2012		($0.24)	($0.23)			View	N/A
5/9/2012		($0.23)	($0.27)			View	N/A
2/22/2012		($0.32)	($0.30)			View	N/A
11/3/2011		($0.32)	($0.31)			View	N/A
8/4/2011		($0.30)	($0.37)			View	N/A
5/9/2011		($0.29)	($0.34)			View	N/A
2/10/2011		($0.40)	($0.33)			View	N/A
10/29/2010	Q3 2010	($1.95)	($2.00)			View	N/A
8/2/2010	Q2 2010	($2.00)	($1.87)			View	N/A
4/30/2010	Q1 2010	($2.20)	($1.98)			View	N/A
2/1/2010	Q4 2009	($2.05)	($2.64)			View	N/A
11/2/2009	Q3 2009	($2.45)	($2.10)			View	N/A
8/3/2009	Q2 2009	($2.80)	($2.72)			View	N/A
5/4/2009	Q1 2009	($3.25)	($2.91)			View	N/A
2/17/2009	Q4 2008	($3.20)	($4.10)			View	N/A
11/5/2008	Q3 2008	($4.00)	($3.37)			View	N/A
8/11/2008	Q2 2008	($3.70)	($3.94)			View	N/A
5/5/2008	Q1 2008	($3.90)	($3.52)			View	N/A
3/4/2008	Q4 2007	($3.90)	($3.77)			View	N/A

(Earnings results data provided by Zacks Investment Research)

MannKind (NASDAQ:MNKD) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 17.73%

Insider Trading History for MannKind (NASDAQ:MNKD)

Institutional Ownership by Quarter for MannKind (NASDAQ:MNKD)

MannKind (NASDAQ MNKD) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/21/2017	Stuart A Tross	VP	Buy	39,840	$2.52	$100,396.80	59,840
12/20/2017	Michael Castagna	CEO	Buy	8,000	$2.29	$18,320.00	35,532
10/13/2017	Kent Kresa	Director	Buy	166,600	$6.00	$999,600.00
8/10/2017	Raymond W Urbanski	CMO	Sell	296	$1.15	$340.40	2,924
6/30/2017	Rosabel Realica Alinaya	SVP	Buy	2,000	$1.23	$2,460.00	30,091
1/3/2017	Matthew J Pfeffer	CEO	Buy	4,540	$0.54	$2,451.60	403,085
1/3/2017	Rosabel Realica Alinaya	SVP	Buy	9,043	$0.54	$4,883.22	140,456
8/26/2016	Michael Castagna	Insider	Buy	17,500	$0.78	$13,650.00	212,500
8/24/2016	Michael Castagna	Insider	Buy	15,000	$0.87	$13,050.00	195,000
8/23/2016	Michael Castagna	Insider	Buy	25,000	$0.94	$23,500.00	180,000
8/15/2016	Matthew J Pfeffer	CEO	Buy	25,000	$0.99	$24,750.00	397,996
8/12/2016	Michael Castagna	Insider	Buy	25,000	$1.00	$25,000.00	75,000
5/17/2016	Michael Castagna	Insider	Buy	50,000	$0.93	$46,500.00	50,000
4/24/2015	Hakan Edstrom	CEO	Sell	73,460	$4.83	$354,811.80
3/27/2015	Hakan Edstrom	CEO	Sell	73,460	$5.21	$382,726.60
2/10/2015	Hakan Edstrom	CEO	Sell	73,460	$7.75	$569,315.00
2/5/2015	David Thomson	VP	Sell	80,000	$7.00	$560,000.00
1/5/2015	Diane Palumbo	VP	Sell	188,999	$5.95	$1,124,544.05
11/24/2014	David Thomson	VP	Sell	118,114	$6.14	$725,219.96
10/3/2014	Juergen Martens	VP	Sell	63,800	$5.48	$349,624.00
8/27/2014	Juergen Martens	VP	Sell	417	$7.60	$3,169.20
8/7/2014	David Thomson	VP	Sell	30,000	$8.16	$244,800.00
7/21/2014	Juergen Martens	VP	Sell	26,458	$9.65	$255,319.70
7/15/2014	Diane Palumbo	VP	Sell	17,901	$10.01	$179,189.01
7/1/2014	Matthew J Pfeffer	CFO	Sell	20,000	$10.44	$208,800.00
6/30/2014	Hakan Edstrom	COO	Buy	1,692	$4.42	$7,478.64
6/27/2014	Juergen Martens	VP	Sell	25,417	$10.53	$267,641.01
6/26/2014	David Thomson	VP	Sell	30,000	$10.51	$315,300.00
6/20/2014	Juergen Martens	VP	Sell	1,458	$10.34	$15,075.72
6/16/2014	Diane Palumbo	VP	Sell	17,902	$10.59	$189,582.18
6/5/2014	Juergen Martens	VP	Sell	120,000	$11.00	$1,320,000.00
6/4/2014	David Thomson	VP	Sell	133,000	$9.95	$1,323,350.00
6/3/2014	Diane Palumbo	VP	Sell	52,957	$9.50	$503,091.50
5/23/2014	Juergen Martens	VP	Sell	25,000	$7.65	$191,250.00
5/19/2014	Juergen Martens	VP	Sell	76,899	$7.50	$576,742.50	139,024
5/15/2014	Diane Palumbo	VP	Sell	18,176	$7.06	$128,322.56	158,858
1/24/2014	Juergen Martens	VP	Sell	50,000	$5.56	$278,000.00	139,450
12/31/2013	Hakan Edstrom	COO	Buy	1,589	$4.53	$7,198.17	729,685
12/20/2013	Juergen Martens	VP	Sell	32,054	$5.00	$160,270.00	139,450
12/11/2013	David Thomson	VP	Sell	150,000	$5.00	$750,000.00	83,752
11/29/2013	Juergen Martens	VP	Sell	48,057	$5.01	$240,765.57	171,504
11/15/2013	Diane Palumbo	VP	Sell	25,000	$5.02	$125,500.00	112,756
8/28/2013	David Thomson	VP	Sell	19,204	$5.78	$110,999.12	40,082
8/26/2013	Juergen Martens	VP	Sell	20,000	$5.52	$110,400.00	136,016
8/1/2013	Matthew J Pfeffer	CFO	Sell	10,000	$8.00	$80,000.00
7/2/2013	Matthew J Pfeffer	CFO	Sell	10,000	$7.00	$70,000.00
6/30/2013	Diane Palumbo	VP	Buy	1,610	$1.96	$3,155.60
6/30/2013	Matthew J Pfeffer	CFO	Buy	7,448	$1.96	$14,598.08
6/3/2013	Diane Palumbo	VP	Sell	66,849	$7.50	$501,367.50
5/16/2013	Diane Palumbo	VP	Sell	26,829	$5.25	$140,852.25
5/15/2013	Matthew J Pfeffer	CFO	Sell	10,000	$5.00	$50,000.00
12/31/2012	Matthew J Pfeffer	CFO	Buy	1,056	$1.95	$2,059.20
12/21/2012	Alfred E Mann	Major Shareholder	Buy	40,000,000	$2.59	$103,600,000.00

(Data available from 1/1/2013 forward)

MannKind (NASDAQ MNKD) News Headlines

Source:

Date	Headline
	MannKind - Afrezza Scripts Dip Again - Q2 Sales Underwhelming Thus Far seekingalpha.com - April 20 at 4:46 PM
	MannKind - Afrezza Scripts Dip Back Below 500 seekingalpha.com - April 15 at 10:09 AM
	MannKind (MNKD) Cut to "Hold" at ValuEngine www.americanbankingnews.com - April 14 at 1:59 PM
	MannKind (MNKD) Enters Oversold Territory April 13, 2018 www.zacks.com - April 13 at 9:20 AM
	MannKind (MNKD) Enters Oversold Territory finance.yahoo.com - April 13 at 9:20 AM
	MannKind And Its Cash Situation seekingalpha.com - April 11 at 4:48 PM
	Form SC 13G MANNKIND CORP Filed by: SABBY MANAGEMENT, LLC www.streetinsider.com - April 9 at 4:44 PM
	Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? April 09, 2018 www.zacks.com - April 9 at 9:14 AM
	Are Options Traders Betting on a Big Move in MannKind (MNKD) Stock? finance.yahoo.com - April 9 at 9:14 AM
	Why MannKind Corporation Stock Sank Last Month finance.yahoo.com - April 9 at 9:14 AM
	MannKind Raises $26.7 Million In Stock Offering - Not Enough seekingalpha.com - April 8 at 5:08 PM
	MannKind (MNKD) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - April 7 at 12:50 PM
	MannKind Modeling And Afrezza Scripts seekingalpha.com - April 7 at 9:30 AM
	MannKind (MNKD) Downgraded to Sell at ValuEngine www.americanbankingnews.com - April 6 at 1:55 PM
	MannKind (MNKD) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 6 at 9:37 AM
	MannKind's stock sinks after direct stock offering finance.yahoo.com - April 6 at 9:23 AM
	Here's Why MannKind Corporation Stock Is Tanking Today finance.yahoo.com - April 6 at 9:23 AM
	MannKind (MNKD) Earns Buy Rating from HC Wainwright www.americanbankingnews.com - April 5 at 7:26 PM
	MannKind (MNKD) Downgraded to Strong Sell at BidaskClub www.americanbankingnews.com - April 4 at 9:30 AM
	MannKind: Playing Poker In A High Stakes Game Holding A Busted Flush Hand seekingalpha.com - April 3 at 4:49 PM
	MannKind Co. (MNKD) Receives Consensus Recommendation of "Sell" from Brokerages www.americanbankingnews.com - April 3 at 1:33 AM
	MannKind (MNKD) Stock Rating Reaffirmed by Maxim Group www.americanbankingnews.com - April 2 at 11:16 AM
	MannKind (MNKD) Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - March 30 at 1:49 PM
	MannKind (MNKD) Lifted to "Hold" at Zacks Investment Research www.americanbankingnews.com - March 29 at 6:22 PM
	MannKind (MNKD) Upgraded to "Buy" by Zacks Investment Research www.americanbankingnews.com - March 29 at 9:06 AM
	MannKind Co. (MNKD) Short Interest Up 6.5% in March www.americanbankingnews.com - March 29 at 3:10 AM
	MannKind Scripts Recover As Q1 Nears Completion seekingalpha.com - March 24 at 4:42 PM
	MannKind's Stone-Age Technology Is Not Rolling Off The Shelves - Seeking Alpha seekingalpha.com - March 21 at 5:00 PM
	MannKind Scripts Dip As Company Works On Debt Structure - Seeking Alpha seekingalpha.com - March 19 at 4:41 PM
	MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference finance.yahoo.com - March 19 at 9:13 AM
	BidaskClub Downgrades MannKind (MNKD) to Sell www.americanbankingnews.com - March 18 at 5:38 PM
	MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference finance.yahoo.com - March 14 at 9:53 AM
	MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference feeds.benzinga.com - March 14 at 8:39 AM
	MannKind (MNKD) Says STAT Study Results Accepted for Presentation at American Diabetes Association - StreetInsider.com www.streetinsider.com - March 13 at 6:38 PM
	MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions finance.yahoo.com - March 13 at 9:17 AM
	MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million finance.yahoo.com - March 12 at 11:42 AM
	Short Interest in MannKind Co. (MNKD) Declines By 3.6% www.americanbankingnews.com - March 12 at 2:14 AM
	MannKind Co. (MNKD) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 9 at 1:27 AM
	Could MannKind Corporation Be a Millionaire-Maker Stock? finance.yahoo.com - March 8 at 5:48 PM
	How Four Managers Outperformed In A Volatile Down Month finance.yahoo.com - March 2 at 9:00 AM
	MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension finance.yahoo.com - March 1 at 5:10 PM
	3 Bright Spots in MannKind Corporation's Q4 Update finance.yahoo.com - February 28 at 5:20 PM
	MannKind (MNKD) Stock Rating Lowered by Maxim Group www.americanbankingnews.com - February 28 at 4:04 PM
	Gene Therapy Holds Out Hope for Diabetics www.prnewswire.com - February 28 at 9:01 AM
	MannKind reports 4Q loss finance.yahoo.com - February 28 at 9:01 AM
	MannKind (MNKD) Announces Earnings Results, Beats Estimates By $0.01 EPS www.americanbankingnews.com - February 27 at 11:14 PM
	MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results finance.yahoo.com - February 27 at 5:20 PM
	MannKind (MNKD) Scheduled to Post Quarterly Earnings on Tuesday www.americanbankingnews.com - February 26 at 9:36 AM
	MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018 finance.yahoo.com - February 23 at 9:03 AM
	Don’t Buy MannKind Corporation Stock Under Any Circumstances investorplace.com - February 12 at 10:14 AM

MannKind (NASDAQ:MNKD) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement

MannKind (NASDAQ MNKD) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff